Malin M Young

US Patent:

7167819, Jan 23, 2007

Filed:

May 26, 2000

Appl. No.:

09/580380

Inventors:

Bradford W. Gibson - Berkeley CA, US
Irwin D. Kuntz - Greenbrae CA, US
Ning Tang - San Francisco CA, US
Gavin Dollinger - San Francisco CA, US
Connie M. Oshiro - Mountain View CA, US
Judith C. Hempel - San Francisco CA, US
Eric W. Taylor - Oakland CA, US
Malin Young - Newark CA, US

Assignee:

Chiron Corporation - Emeryville CA
The Regents of the University of California - Oakland CA

International Classification:

G06G 7/58
G01N 31/00
G01N 24/00
G12P 19/42

US Classification:

703 12, 702 27, 435 86, 436173

Abstract:

The present invention provides a fast and efficient method for determining the three-dimensional conformation of a protein. The steps of the method of the invention include: 1) formation of physical distance constraints, e. g. , forming intramolecular chemical crosslinks of known size between residues of a protein; 2) enriching the number of the molecules that have intramolecular chemical crosslinks in the reaction pool, e. g. , using size separation to remove proteins with intermolecular bonds; 3) exposing the enriched reaction pool to a protease that cuts the protein at specific sites to produce peptide fragments; 4) measuring the size of the peptide fragments to determine linkage sites with a certain spatial relationship in the protein; and 5)interpreting the data produced to determine spatial geometry and protein structure based on the deduced spatial relationship of the linkage sites. The information is preferably analyzed with aid from a computer system, which can be used to generate and/or analyze distance constraints between amino acids.

US Patent:

7368290, May 6, 2008

Filed:

May 12, 2003

Appl. No.:

10/437268

Inventors:

Gary Kruppa - San Francisco CA, US
Joseph S. Schoeniger - Oakland CA, US
Malin M. Young - Livermore CA, US

Assignee:

Sandia National Laboratories - Livermore CA

International Classification:

G01N 33/00
G01N 24/00

US Classification:

436 86

Abstract:

The present invention relates to novel methods of determining the sequence and structure of proteins. Specifically, the present invention allows for the analysis of intact proteins within a mass spectrometer. Therefore, preparatory separations need not be performed prior to introducing a protein sample into the mass spectrometer. Also disclosed herein are new instrumental developments for enhancing the signal from the desired modified proteins, methods for producing controlled protein fragments in the mass spectrometer, eliminating complex microseparations, and protein preparatory chemical steps necessary for cross-linking based protein structure determination. Additionally, the preferred method of the present invention involves the determination of protein structures utilizing a top-down analysis of protein structures to search for covalent modifications. In the preferred method, intact proteins are ionized and fragmented within the mass spectrometer.

US Patent:

61403687, Oct 31, 2000

Filed:

May 4, 1998

Appl. No.:

9/072484

Inventors:

George L. Kenyon - San Francisco CA
Margaret Stauber - Germantown MD
Karl Maurer - Ross CA
Dolan Eargle - San Francisco CA
Angelika Muscate - Loerrach, DE
Andrew Leavitt - San Francisco CA
Diana C. Roe - Newark CA
Todd J. A. Ewing - San Francisco CA
Allan G. Skillman - San Francisco CA
Edward Arnold - Belle Mead NJ
Irwin D. Kuntz - Greenbrae CA
Malin Young - San Francisco CA

Assignee:

The Regents of the University of California - Oakland CA
Rutgers, The University of New Jersey - New Brunswick NJ

International Classification:

A61K 31175

US Classification:

514593

Abstract:

The present invention relates to a novel class of compounds that are potent inhibitors of HIV reverse transcriptase and HIV integrase. In addition to being multienzyme inhibitors, the inventive compounds of the present invention are remarkable in at least two other respects. First, they do not appear to be toxic to cells at typical therapeutic concentrations. Second, they appear to be equally effective against mutant strains of HIV reverse transcriptase commonly found in patients who have developed resistance to current reverse transcriptase inhibitors. Because the inventive compounds show promise in combatting viral resistance and are potent inhibitors of both HIV reverse transcriptase and integrase, they are ideal candidates for use in combination with existing therapies or alone in treating AIDS or HIV infection.